At Myosin Therapeutics, we’re tackling aggressive, treatment-resistant cancers by targeting a completely new frontier in cancer biology—the molecular nanomotors that power cancer cell movement, invasion, and survival.
Myosin Therapeutics is a clinical and R&D-stage biotech C-corp incorporated in Delaware and based in South Florida.
The company’s innovative science was developed collaboratively in the labs of Drs. Miller, Griffin, and Kamenecka at the Department of Molecular Medicine, Wertheim UF Scripps Institute for Biomedical Innovation & Technology—a University of Florida research institute dedicated to new treatments.
Founded to pioneer an entirely new therapeutic approach, Myosin Therapeutics modulates molecular nanomotors—the cellular machines that control movement and behavior—to address diseases underserved by current therapies.
Primary focus: aggressive, treatment-resistant cancers that have not benefited from recent immunotherapy advances. Additional programs target brain disorders.
Leadership Team
- Dr. Miller, PhD – CEO, Founder, Board Chair
Trained in neuroscience and venture capital. Received a presidential award for scientists and engineers; named BioFlorida Entrepreneur of the Year. - Dr. Smith, MD, PhD, MBA – Chief Medical Officer
Over 25 years in healthcare, with senior roles at Bristol Myers Squibb, AstraZeneca, and Merck. Oversaw >100 clinical trials and 20 regulatory approvals. Delivered ~$20B in value through corporate exits in prior board roles. - Drs. Griffin and Kamenecka, PhD – Co-Chief Scientific Officers, Founders
Collectively >50 years in drug discovery and development across academia, biotech, and pharma (e.g., Merck).
Key Support
- Ms. Finn – Head of Clinical Operations
- Ms. Ahmuty – Head of Regulatory
- Ms. Itzkowitz – Operations Director
The executive team is backed by decades of specialized experience across clinical, regulatory, and operational functions.
Myosin Therapeutics is advancing MT-125, a first-in-class selective non-muscle myosin II inhibitor, toward clinical translation in glioblastoma and other solid/hematological cancers.
Strategic Approach
- Capital-Efficient Clinical Development
Focused Phase 1/2 STAR-GBM trial, designed in close collaboration with the FDA to support rapid progression to pivotal Phase 2/3 and accelerated approval. - Fully Funded Early Trial
STAR-GBM trial financed by NCI funding, preserving equity and enabling flexibility. - Partnership Flexibility
Open to licensing/co-development with large pharma or retaining ownership via larger financing round. - Timeline Milestones
Safety data expected Summer 2026; pivotal Phase 2/3 in Q4 2027; pipeline expansion into broader oncology indications.
Active academic/clinical partnerships include Mayo Clinic, UF Scripps, Johns Hopkins, and MD Anderson to accelerate biomarker discovery and translational endpoints.
This dual-path strategy maximizes MT-125’s impact and long-term commercial potential while advancing the broader nanomotor pipeline.
Myosin Therapeutics pursues a staged, de-risked path to revenue with significant upside potential.
Near-Term Revenue Drivers
- Non-Dilutive Funding
Additional grants from state/federal programs and foundations (recent $4.5M application submitted October 2025) to support ongoing and expansion trials. - Strategic Partnerships
Licensing or co-development deals post-positive Phase 1 data, including upfront payments, milestones, and royalties. - Platform Extension
Leverage NMII chemistry for additional oncology/fibrosis indications and advance pipeline for further out-licensing.
Longer-Term Potential
- Direct Commercialization
Retain MT-125 for orphan oncology markets via accelerated approval and exclusivity (if financed internally).
This hybrid model—grants, milestone deals, and selective commercialization—positions Myosin Therapeutics as the leader in molecular nanomotor-targeted therapeutics.
Investment Opportunity
Myosin Therapeutics is raising a Series A (structured as a “Series B-like” round) to capitalize on the transformative potential of molecular nanomotors, with MT-125 as an Oncology Pipeline in a Bottle.
Closing targeted post-initial safety data from the three-site STAR-GBM Phase 1/2 trial.
Use of Proceeds
- Pivotal Phase 2/3 in Glioblastoma
Prepare and launch multi-site study across chemotherapy-resistant and responsive patients for approval. - Indication Expansion
Phase 1/2 trials in acute myeloid leukemia (AML) and pancreatic adenocarcinoma. - Pipeline Advancement
Further develop nMOTOR platform and first-in-class small molecules for oncology.
Investors gain multiple near-term value inflections: potential licensing/acquisition after Phase 1 safety or Phase 2 efficacy, plus ongoing platform expansion. We welcome strategic partners who share our vision of transforming cancer therapy through selective control of tumor mechanics.
nMOTOR Platform & Pipeline
- Broad Platform
Identifies small-molecule modulators of any of the ~100 human molecular nanomotors—most implicated in disease or underexplored due to lack of tools. - Pipeline Compounds
Multiple first-in-class candidates. - Clinical Candidates
MT-110 (IND preparation for methamphetamine use disorder) and MT-125 (IND opened). - Regulatory Designations
MT-125 granted Orphan Drug and Fast Track for glioblastoma. - Clinical Progress
First patient dosing in STAR-GBM Phase 1/2 trial: December 2025. Potential synergy with radiation; broad oncology applicability (AML, pancreatic cancer).
Science externally validated by multiple peer-reviewed NIH grants and two recent publications in Cell.
Myosin Therapeutics has secured substantial venture investment and non-dilutive grant funding.
Venture Investment
| Round | Year | Amount | Notes |
|---|---|---|---|
| Seed | 2023 | $3M | Closed |
| Seed 1 | January 2025 | $3M | Post-money valuation $28M |
Grants
| Source | Program | Year | Amount |
|---|---|---|---|
| NIDA | Start A Startup | 2020 | $10K |
| Yale | Innovation to Impact | 2021 | $40K |
| NIDA | Fast Track SBIR | 2022 | $3M |
| NCI | Fast Track STTR | 2022 | $2.7M |
| NIDA | Direct to Phase II SBIR | 2025 | $3M |
| NCI | CRP SBIR | 2025 | $250K |
| NCI | Phase IIB Bridge | 2025 | $4.5M |
